GLP-1 medications like Ozempic require dental hygienists to move beyond simply documenting them and instead assess how the medication affects the patient's oral health through questions about hydration, eating patterns, salivary changes, and clinical findings that may not match previous risk assessments.
- Take a medication history, not just a medical history: Ask how long the patient has been taking the GLP-1, what it manages, dose changes, and how they feel since starting it.
- Watch for complex oral changes: GLP-1s may cause dry mouth, erosion, gum sensitivity, and bleeding, but these result from multiple factors, including hydration, eating patterns, and salivary protection, not one cause alone.
- Clinical presentation may not match previous risk: If a patient's mouth shows unexpected changes, like enamel erosion or bleeding gums despite good plaque control, ask about new medications or injections, appetite changes, nausea, or reflux.
- Individualize care based on assessment: Avoid giving all GLP-1 patients the same recommendations; instead, use clinical reasoning to connect medication changes with oral findings and adjust preventive strategies accordingly.
GLP-1 medications such as Ozempic, Wegovy, and Mounjaro are regularly appearing on patients’ medication lists. Yet many clinicians still document the medication, check the box, and move on.
The more important question is whether that medication changes what we ask, assess, and notice during the hygiene appointment. GLP-1s may be prescribed for diabetes, obesity management, or another medical need. We cannot assume why a patient is taking one; our responsibility is to understand what the medication may mean for the patient sitting in our chair.
Take a medication history, not just a medical history
Kelly Tanner, PhD, RDH.
My friend and pharmacology expert Dr. Tom Viola once made a distinction that completely reframed health history for me: Don't just take a medical history. Take a medication history. A diagnosis tells us what condition the patient has, but the medications may offer additional clues about how that condition is being managed.
When a patient reports taking a GLP-1 medication, the name alone tells us very little. How long has the patient been taking it? What is it helping the physician manage, and has the dose changed recently? Most importantly, how has the patient been feeling since beginning it?
These questions aren’t meant to turn hygienists into pharmacologists. They help us connect a change in the patient's medical care with a change we may be seeing clinically. The medication list is not the end of the assessment; it is where our curiosity should begin.
When the mouth stops matching the patient
Imagine a patient you have treated for six years. She has historically maintained excellent home care and a low caries risk, but today you notice changes on the palatal surfaces of her maxillary anterior teeth. The enamel looks thinner, the tissues look different, and the erosion is more pronounced than in your previous photographs.
Nothing in her health history explains the change. She may not have listed a GLP-1 medication because she forgot, did not consider it relevant to dental care, or did not want to disclose that she was taking it. This is where hygienists often begin connecting the dots before the patient tells us what has changed.
The usual dietary questions are still appropriate, but we may need to widen the conversation. We can ask whether she has started any new medications or injections, experienced changes in appetite or hydration, or noticed nausea, vomiting, or reflux.
These questions allow the patient to share more without feeling as though we are assuming weight, diabetes, or why a medication may have been prescribed. Sometimes the mouth reveals the change before the health history does. Our role is not to diagnose medication use based on an oral finding. It is to recognize that the clinical presentation no longer matches the patient's previous pattern and ask the questions that may help explain why.
Dry mouth is not the whole story
It is tempting to hear GLP-1 and immediately think dry mouth, but the clinical picture is usually more complex. A patient may be taking several medications, drinking less water, eating differently, experiencing nausea, or managing diabetes. Any combination of these factors could affect oral comfort, salivary protection, caries risk, and tissue condition. That is why we should be careful about automatically attributing the patient's dry mouth to a GLP-1 medication. Instead, assess what is actually happening. Does the patient report oral dryness, and does the saliva appear reduced, thick, stringy, or foamy?
The distinction matters because saliva does far more than make the mouth feel comfortable. It supports remineralization, buffers acid, helps cleanse, and it protects oral tissues. When that protection changes, the patient's previous risk assessment may no longer reflect what is happening today.
The patient may tell you something feels different
Recently, I evaluated a patient taking a GLP-1 medication who reported that her gums had become extremely sore and bled easily. Her plaque score was 22%, yet 98% of her sites bled during probing. She had no probing depths greater than 3 mm. Before I probed, she told me she didn't want to brush because her mouth and teeth felt “weird.” Her tissues were dry, uncomfortable, and so sensitive that her usual brushing routine had become painful. An extra-soft toothbrush helped her brush comfortably again, but the important lesson wasn't the toothbrush recommendation.
The bigger question was why the clinical presentation didn't match the local factors. When inflammation, discomfort, or tissue changes cannot be adequately explained by biofilm, we need to look beyond repeatedly telling the patient to brush better. The body may be giving us information that requires a broader assessment.
This is where clinical reasoning begins
A bleeding site is not just a bleeding site. Dry mouth is not simply dry mouth, and erosion is not always the result of an acidic beverage.
We collect clues about what has changed, what doesn't fit, and what we need to ask next. GLP-1 medications create a new hygiene conversation because they may intersect with hydration, eating patterns, acid exposure, saliva, caries risk, periodontal inflammation, and the patient's underlying medical condition.
The answer is not to give every patient taking one of these medications the same recommendations. That is not individualized, risk-based care. The challenge is knowing which questions to ask, what oral changes deserve closer attention, and how to translate those findings into appropriate patient communication and preventive care. A short checklist or a single product recommendation can't fully address that.
Move beyond documenting the medication
The next time Ozempic, Wegovy, Mounjaro, or another GLP-1 medication appears on a patient's health history, resist the urge to record it and continue with the appointment. Become curious about what has changed since the medication started and whether the patient's mouth is telling you something the health history hasn't yet revealed.
In my online course, GLP-1 and the New Hygiene Conversation, I take this discussion further. We explore the oral findings to watch for, the questions that uncover relevant symptoms, and how to individualize care without overwhelming or judging the patient. If these medications are already in your chair, you need to be prepared to have this clinical conversation.
Kelly Tanner, PhD, RDH, is a contributing author to DrBicuspid, where she shares insights and strategies to empower dental hygienists in their careers. As a leader in clinical training, professional development, and team dynamics, Tanner provides resources to help hygienists elevate their practice and personal growth. For further support, join her free Facebook group, Next Level Dental Hygiene Career and Personal Development, and explore group training and on-demand courses at www.nextleveldentalhygiene.com.
The comments and observations expressed herein do not necessarily reflect the opinions of DrBicuspid.com, nor should they be construed as an endorsement or admonishment of any particular idea, vendor, or organization.
